Contineum Therapeutics (CTNM) Change in Accured Expenses (2023 - 2026)

Contineum Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 23.17% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at -$1.2 million (down 558.66% YoY), while the FY2025 annual figure was -$516000.0, down 122.41% from the prior year.
• Change in Accured Expenses was -$3.5 million for Q1 2026 at Contineum Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q4 2024 to a low of -$3.5 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$11076.9 across 4 years, with a median of -$102000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses surged 283.05% in 2024, then slumped 653.16% in 2025.
• A 4-year view of Change in Accured Expenses shows it stood at -$1.6 million in 2023, then soared by 283.05% to $2.9 million in 2024, then dropped by 28.62% to $2.1 million in 2025, then plunged by 268.1% to -$3.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.5 million (Q1 2026), $2.1 million (Q4 2025), and $351000.0 (Q3 2025), per Business Quant data.